Analyst Research
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: GlobalData
|
$250.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
PAREXEL International Corp. Issues Q4, FY 2012 Mixed Guidance
PAREXEL International Corp. announced that for fourth quarter of 2012, it expects consolidated service revenue of $376.0-$381.0 million, GAAP earnings per diluted share in the range of $0.28-$0.30. For fiscal 2012, it expects consolidated service revenue to be in the range of $1.380-$1.385 billion, GAAP earnings per diluted share in the range of $1.03-$1.05, and adjusted earnings per diluted share (EPS) in the range of $1.04-$1.06 (which exclude the impact of restructuring and related charges and certain Q3 fiscal 2012 tax benefits). According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $366.4 million and EPS of $0.37 for fourth quarter of 2012; revenue of $1.366 billion and EPS of $1.12 for fiscal 2012.
Latest Developments for PAREXEL International Corp
- Parexel International Corp Issues Q4 2013 Guidance; Raises FY 2013 Guidance
- Parexel International Corp Reaffirms FY 2013 EPS Guidance-Conference Call
- Parexel International Corp Issues Q3 2013 Guidance In Line With Analysts' Estimates; Raises FY 2013 Guidance
- Parexel International Corp Announces Acquisition of Liquent, Inc
Latest Key Developments in Biotechnology
- Norda ASA Plans Delisting from Oslo Stock Exchange
- Stemline Therapeutics Inc Announces Closing Of $60 Million Public Offering Of Common Stock
- Clavis Pharma ASA Appoints Interim Chairman and Acting CEO
- Oncolytics Biotech Inc Meets Primary Endpoint For First Stage Of U.S. Phase 2 Metastatic Melanoma Trial
- Share this
- Link this
- Digg this


Follow Reuters